We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WASHINGTON — Patients with inflammatory arthritis who ...
Guselkumab and risankizumab demonstrated the highest adjusted survival time for effectiveness (RMST, 1.93 years for both; 95% CI, 1.91-1.95 and 1.90-1.96 years, respectively). Risankizumab showed the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among targeted therapies, patients with VEXAS syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback